WO2005016236A3 - Antibodies that immunospecifically bind to trail receptors - Google Patents

Antibodies that immunospecifically bind to trail receptors Download PDF

Info

Publication number
WO2005016236A3
WO2005016236A3 PCT/US2004/013900 US2004013900W WO2005016236A3 WO 2005016236 A3 WO2005016236 A3 WO 2005016236A3 US 2004013900 W US2004013900 W US 2004013900W WO 2005016236 A3 WO2005016236 A3 WO 2005016236A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
immunospecifically bind
relates
methods
trail receptors
Prior art date
Application number
PCT/US2004/013900
Other languages
French (fr)
Other versions
WO2005016236A2 (en
Inventor
Theodora Salcedo
Craig A Rosen
Vivian R Albert
Robin Humphreys
Tristan John Vaughan
Original Assignee
Human Genome Sciences Inc
Theodora Salcedo
Craig A Rosen
Vivian R Albert
Robin Humphreys
Tristan John Vaughan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Theodora Salcedo, Craig A Rosen, Vivian R Albert, Robin Humphreys, Tristan John Vaughan filed Critical Human Genome Sciences Inc
Priority to CA002524737A priority Critical patent/CA2524737A1/en
Priority to EP04775943A priority patent/EP1633316A4/en
Priority to US10/981,465 priority patent/US20050214205A1/en
Priority to US10/981,673 priority patent/US20050214207A1/en
Priority to US10/981,691 priority patent/US20050214208A1/en
Priority to US10/981,621 priority patent/US20050214206A1/en
Publication of WO2005016236A2 publication Critical patent/WO2005016236A2/en
Priority to US11/391,395 priority patent/US20060269555A1/en
Publication of WO2005016236A3 publication Critical patent/WO2005016236A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR7. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR7 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR7.
PCT/US2004/013900 2001-12-20 2004-05-05 Antibodies that immunospecifically bind to trail receptors WO2005016236A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002524737A CA2524737A1 (en) 2003-05-06 2004-05-05 Antibodies that immunospecifically bind to trail receptors
EP04775943A EP1633316A4 (en) 2003-05-06 2004-05-05 Antibodies that immunospecifically bind to trail receptors
US10/981,465 US20050214205A1 (en) 2001-12-20 2004-11-05 Antibodies that immunospecifically bind to TRAIL receptors
US10/981,673 US20050214207A1 (en) 2001-12-20 2004-11-05 Antibodies that immunospecifically bind toTRAIL receptors
US10/981,691 US20050214208A1 (en) 2001-12-20 2004-11-05 Antibodies that immunospecifically bind to TRAIL receptors
US10/981,621 US20050214206A1 (en) 2001-12-20 2004-11-05 Antibodies that immunospecifically bind to TRAIL receptors
US11/391,395 US20060269555A1 (en) 2001-12-20 2006-03-29 Antibodies that immunospecifically bind to TRAIL receptors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46809203P 2003-05-06 2003-05-06
US60/468,092 2003-05-06
US49514003P 2003-08-15 2003-08-15
US60/495,140 2003-08-15

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US10/981,465 Continuation-In-Part US20050214205A1 (en) 2001-12-20 2004-11-05 Antibodies that immunospecifically bind to TRAIL receptors
US10/981,691 Continuation-In-Part US20050214208A1 (en) 2001-12-20 2004-11-05 Antibodies that immunospecifically bind to TRAIL receptors
US10/981,621 Continuation-In-Part US20050214206A1 (en) 2001-12-20 2004-11-05 Antibodies that immunospecifically bind to TRAIL receptors
US10/981,673 Continuation-In-Part US20050214207A1 (en) 2001-12-20 2004-11-05 Antibodies that immunospecifically bind toTRAIL receptors
US11/391,395 Continuation-In-Part US20060269555A1 (en) 2001-12-20 2006-03-29 Antibodies that immunospecifically bind to TRAIL receptors

Publications (2)

Publication Number Publication Date
WO2005016236A2 WO2005016236A2 (en) 2005-02-24
WO2005016236A3 true WO2005016236A3 (en) 2007-06-14

Family

ID=34197757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013900 WO2005016236A2 (en) 2001-12-20 2004-05-05 Antibodies that immunospecifically bind to trail receptors

Country Status (3)

Country Link
EP (1) EP1633316A4 (en)
CA (1) CA2524737A1 (en)
WO (1) WO2005016236A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2360255E (en) 2005-03-25 2015-04-08 Nat Res Council Canada Method for isolation of soluble polypeptides
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
US9908942B2 (en) 2013-03-14 2018-03-06 Bayer Healthcare, Llc Monoclonal antibodies against antithrombin β

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
WO2002097033A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
AU2002361784A1 (en) * 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRIFFITH T.S. ET AL.: "Functional analysis of TRAIL receptors using monoclonal antibodies", J. IMMUNOL., vol. 162, no. 5, 1 March 1999 (1999-03-01), pages 2597 - 2605, XP000918935 *
See also references of EP1633316A4 *
VERMOT-DESROCHES C. ET AL.: "Characterization of monoclonal antibodies directed against trail or trail receptors", CELL IMMUNOL., vol. 236, no. 1-2, July 2005 (2005-07-01) - August 2005 (2005-08-01), pages 86 - 91, XP005197728 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
EP1633316A2 (en) 2006-03-15
EP1633316A4 (en) 2008-04-02
WO2005016236A2 (en) 2005-02-24
CA2524737A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
WO2003054216A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2002097033A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2002094192A3 (en) Antibodies against tumor necrosis factor delta (april)
DE60028970D1 (en) AT HER2 BINDING PEPTIDE COMPOUNDS
WO2003055979A3 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
MXPA02012434A (en) Antibodies that immunospecifically bind to blys.
WO2004013287A3 (en) Antibodies against c3a receptor
WO2004000997A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
BR0306973A (en) Anti-igf-ir Antibodies and their applications
WO2001055448A8 (en) Nucleic acids, proteins, and antibodies
WO2004100898A3 (en) Therapeutic use of anti-cs1 antibodies
WO2003089575A3 (en) Antibodies that specifically bind to tl5
WO2004003144A3 (en) Antibodies that specifically bind to reg iv
WO2003102136A3 (en) Antibodies that specifically bind to neurokinin b
WO2005016236A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003085093A3 (en) Antibodies that specifically bind to gmad
WO2003042367A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2002079377A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2004016753A3 (en) Antibodies that immunospecifically bind to trail receptors
ATE518884T1 (en) ANTIBODIES SPECIFICALLY BINDING TO CHEMOKIN BETA-4
WO2003086301A3 (en) Antibodies that specifically bind to tr2
WO2005018536A3 (en) Agonist antibodies that specifically bind the glucagon like peptide-1 receptor
WO2003078572A3 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
WO2003022998A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2524737

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004775943

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004775943

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11391395

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11391395

Country of ref document: US